{"disease":{"id":"primary-progressive-multiple-sclerosis-ppms","name":"primary progressive multiple sclerosis ppms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06677710","title":"IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":34,"lead_sponsor_name":"Indapta Therapeutics, INC.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}